Delta 9 Reports Financials for Q3 2019 and Announces Grant of Stock Options
Press Release
WINNIPEG, MB – November 13, 2019 – DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: VRNDF) (“Delta 9” or the “Company”), is pleased to announce financial and operating results for the three-month and nine-month period ending September 30, 2019.
Financial Highlights for Q3, 2019
- Operating revenues of $6.7 million for the third quarter of 2019, up 432%, from $1,251,213 for the same quarter last year.
- Adjusted EBITDA[1] was $(849,760) compared to $(2,551,710) in Q3, 2018.
- Gross profit[2] of $2.0 million for the third quarter of 2019, up 550%, from $312,480 for the same quarter last year.
- Gross profit margin was 31% for Q3, 2019.
Financial Highlights for the nine months of 2019
- Record operating revenues of $21.2 million, up 821%, from $2.3 million for the same period last year.
- Gross profit2 of $6.8 million, up 799%, from $756,644 for the same period last year.
- Gross profit margin was 32% for the nine months of 2019.
“Management would point to the significant year over year increases in net revenue as a positive indication that the Company’s initial quarters of sales in the recreational use cannabis market have been able to contribute significant revenue growth,” said John Arbuthnot, CEO of Delta 9. “Management attributes the decrease in sequential quarterly revenue to a timing issue with revenue in its business to business (B2B) division which was down from the 2nd quarter of 2019.”
The Company’s retail division generated $4.4 million in revenue in the 3rd quarter of 2019 which was up 24% or $840,208 sequentially. The wholesale division generated $2.2 million in revenue for the same period and was down 23% or $684,138.
“Delta 9 will continue to drive sustainable long-term shareholder value by leveraging its strong brand positioning in Western Canadian markets, expanding our various wholesale supply contracts and scaling up our cultivation operations,” said John Arbuthnot, CEO of Delta 9. “We are taking a responsible and compliant approach to growing our business to build an authentic Delta 9 brand as we pursue retail opportunities in the Western Canadian market place.”
3rd Quarter Operational Highlights
- The company entered into a binding letter of intent to acquire two retail stores in Alberta that continues the strategy of establishing a chain of Delta 9 branded retail stores across Canada. Delta 9’s goal is to add an additional 12 retail stores over the next 24 months.
- The newest Delta 9 Cannabis Store is the largest cannabis retail store in the Thompson, Manitoba area, offering customers an open and modern shopping décor, highly trained staff and a wide range of products, including dried cannabis flower, cannabis oil and a full assortment of cannabis accessories.
- The Company installed and began crop production of cannabis in an additional 48 of its proprietary “Grow Pods”, bringing its total number of Grow Pods in production to 202 within its Winnipeg production facility (the “Delta Facility”).
- The additional 48 Grow Pods will increase production by 1,150 kilograms per year of dried cannabis flower production, bringing the Company’s overall anticipated production capacity to 5,350 kilograms of dried cannabis flower per year.
- There is another 95 Grow Pods in place and ready for planting once Delta 9 receives approval from Health Canada, which is expected shortly. This will bring the total Grow Pods in production to 297 within the Delta Facility.
- The Company is continuing with its planned Phase II expansion of the Delta Facility to increase cannabis production to 16,500 kilograms per year.
- After successfully passing all inspections, Delta 9 received a renewal of its cannabis cultivation license for a three-year term after fulfilling Health Canada’s rigorous specifications.
Summary of Quarterly Results:
| Consolidated Statement of Net Loss | Q3 2019 | Q2 2019 | Q1 2019 | Q4 2018 |
| Revenue | $6,662,137 | $8,886,155 | $5,632,184 | $5,270,217 |
| Cost of Sales | 4,628,070 | 5,936,975 | 3,815,930 | 4,015,644 |
| Gross Profit Before Unrealized Gain From Changes In Biological Assets | 2,034,067 | 2,949,180 | 1,816,254 | 1,254,573 |
| Unrealized gain from changes in fair value of biological assets (Net) | 1,388,863 | 586,366 | 2,406,735 | 2,087,367 |
| Gross Profit (Loss) | $3,422,930 | $3,535,546 | $4,222,989 | $3,341,940 |
| Expenses | ||||
| General and Administrative | 2,681,388 | 3,075,803 | 3,451,900 | 3,296,351 |
| Sales and Marketing | 1,151,158 | 1,324,537 | 969,202 | 1,389,241 |
| Share Based Compensation | 215,456 | 244,848 | 748,067 | 807,834 |
| Total Operating Expenses | $4,048,002 | $4,645,188 | $5,169,169 | $5,493,426 |
| Adjusted EBITDA (Loss) 1 | (849,760) | (663,705) | (1,978,778) | (2,815,412) |
| Income (Loss) from Operations | $(625,072) | $(1,109,642) | $(946,180) | $(2,151,486) |
| Other Income/ Expenses | $(642,190) | $(206,231) | $17,260,525 | $69,033 |
| Net Income (Loss) | $(1,267,262) | $(1,315,873) | $16,314,345 | $(2,082,453) |
| Basic and Diluted Earnings (Loss) Per Share | $(0.02) | $(0.01) | $0.19 | $(0.02) |
- Adjusted EBITDA is a non-IFRS measure, and is calculated as earnings before interest, tax, depreciation and amortization, share-based compensation expense, fair value changes and other non-cash items.
The following chart provides a breakdown of the Company’s revenue by segment:
| Revenue from the Sale of Cannabis | Three-month period ending September 30, 2019 | Three-month period ending June 30, 2019 |
| Wholesale Cannabis Revenue | $2,233,509 | $2,917,647 |
| Retail Cannabis Revenue | 4,359,614 | 3,519,406 |
| Medicinal Cannabis Revenue | 66,770 | 87,416 |
| Revenue from Other categories | ||
| Business to business activities | 222,944 | 2,165,167 |
| Merchandise and cannabis devices | 158,721 | 184,164 |
| Other | 31,010 | 62,976 |
| Sub total | $7,072,568 | $8,936,776 |
| (Less) Excise Taxes | 410,431 | 50,621 |
| Net Revenue | $6,662,137 | $8,886,155 |
Discussion of Operations:
| Key Performance Indicators | For the three-month period ending September 30, 2019 | For the three-month period ending June 30, 2019 |
| Production/ Wholesale Unit | ||
| Total Grams Produced | 871,516 | 675,233 |
| Direct Production Cost Per Gram* | $1.08 | $1.05 |
| Total Cost Per Gram** | $1.21 | $1.21 |
| Total Grams Released for Sale | 519,596 | 565,599 |
| Total Grams Sold (Medical and Recreational) | 548,981 | 527,693 |
| Avg Selling Price per Gram | $4.19 | $5.63 |
| Retail Unit | ||
| Total Grams Sold (Retail) | 349,410 | 282,336 |
| Avg Selling Price per Gram | $12.47 | $12.42 |
| Number of Transactions Processed | 108,438 | 84,882 |
| Avg Transaction Size | $41.67 | $41.46 |
*Direct Production Cost per gram includes direct labour, nutrients, utilities, growing materials and supplies costs
**Total Cost per gram includes Direct Production Cost per gram plus processing labour, packaging, bottling, and labelling costs
A comprehensive discussion of Delta 9’s financial position and results of operations is provided in the Company’s Management Discussion & Analysis for the third quarter and nine months of 2019 filed on SEDAR and can be found at www.sedar.com.
Q3 Results 2019 Conference Call
Delta 9 has scheduled a conference call to discuss the results for third quarter of 2019. The conference call will be hosted November 14, 2019 at 9:00 a.m. Eastern Time by John Arbuthnot, Chief Executive Officer and Jim Lawson, Chief Financial Officer, followed by a question and answer period.
| DATE: | November 14, 2019 |
| TIME: | 9:00 a.m. Eastern Time |
| DIAL IN # | 1-888-886-7786 |
| REPLAY: | 1-877-674-6060 Available until 12:00 midnight Eastern Time, February 28, 2020 |
| REPLAY PASSCODE: | 107644 # |
Grant of Stock Options
Delta 9 also wishes to announced that it has granted, effective today, an aggregate of 3,000,000 stock options (each an “Option”) to certain directors, officers, employees and consultants of the Company in accordance with the Company’s current stock option plan. Each Option is exercisable into one common share (a “Share”) of the Company at a price of $0.55 per Share for a period of five years from the date of grant, being today. The Options will vest over twelve months, with 1,500,000 (50%) vesting six months from the date hereof and the remaining 1,500,000 (50%) vesting 12 months from the date hereof.
“Stock Options play a key role in compensating our employees and aligning their interests with those of the shareholder,” said John Arbuthnot, CEO of Delta 9, “Delta 9 has an inclusive options program which allows for all eligible staff to receive options based on their position and performance. We are very proud of our staff’s operating performance to date; this grant will allow for over 185 eligible staff to receive stock options in Delta 9.”
For more information contact:
Investor & Media Contact:
Ian Chadsey VP Corporate Affairs
Mobile: 204-898-7722
E-mail: ian.chadsey@delta9.ca
IBF4
